The use of modern imaging technologies in radiation therapy of cervical cancer

详细信息    查看全文

• 作者：Angel I. Blanco (1)
  Larissa A. Meyer (2)
  Verghese George (3)
  Bin S. Teh (4)
  Adan Rios (5)
  Kara Ferachi (6)
  Matthew Rodriguez (6)
  Anneliese Gonzalez (7)
  John Dalrymple (2)
  
  1. Radiation Therapy Services ; Memorial Hermann Cancer Center ; Memorial Hermann Medical Plaza ; 6400 Fannin ; Ste #220 ; Houston ; TX ; 77030 ; USA
  2. Department of Obstetrics ; Gynecology and Reproductive Sciences ; Division of Gynecologic Oncology ; Houston ; TX ; USA
  3. Section of Abdominal Imaging ; Department of Radiology ; University of Texas Health Science Center at Houston ; Houston ; TX ; USA
  4. Department of Radiation Oncology ; The Methodist Hospital ; Cancer Center and Research Institute ; Houston ; TX ; USA
  5. Internal Medicine Department ; Division of Oncology ; The University of Texas Health Science Center at Houston ; Houston ; TX ; USA
  6. Landauer Medical Physics ; 2 Science Road ; Glenwood ; IL ; 60425 ; USA
  7. Internal Medicine Department ; Division of Oncology ; The University of Texas Health Science Center at Houston ; Houston ; TX ; USA
  
• 关键词：Cervical cancer ; HDR ; MRI ; Chemoradiation
• 刊名：Journal of Radiation Oncology
• 出版年：2015
• 出版时间：March 2015
• 年：2015
• 卷：4
• 期：1
• 页码：1-10
• 全文大小：512 KB
• 参考文献：1. Jemal, A, Siegel, R, Xu, J (2010) Cancer statistics. CA Cancer J Clin 60: pp. 277-300 CrossRef
  2. Siegel, R, Naishadham, D, Jemal, A (2012) Cancer statistics. CA Cancer J Clin 62: pp. 10-29 CrossRef
  3. Tod, MC, Meredith, WJ (1938) A dosage system for use in the treatment of cancer of the uterine cervix. Br J Radiol 11: pp. 809-824 CrossRef
  4. National Institute of Health (1999) NCI issues clinical announcement on cervical cancer: chemotherapy plus radiation improves survival. http://www.nih.gov/news/pr/feb99/nci22.html
  Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database Syst Rev.
  5. Balleyguier, C, Sala, E, Cunha, T (2011) Staging of uterine cervical cancer with MRI: guidelines of the European Society of Urogenital Radiology. Eur Radiol 21: pp. 1102-1110 CrossRef
  6. Duenas-Gonzalez, A, Zarba, JJ, Patel, F (2011) Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol 29: pp. 1678-1685 CrossRef
  7. ClinicalTrials.gov (2012) Cisplatin and radiation therapy with or without carboplatin and paclitaxel in patients with locally advanced cervical cancer. [cited 2013; A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: the OUTBACK trial]. http://clinicaltrials.gov/show/NCT01414608
  8. Logsdon, MD, Eifel, PJ (1999) FIGO IIIB squamous cell carcinoma of the cervix: an analysis of prognostic factors emphasizing the balance between external beam and intracavitary radiation therapy. Int J Radiat Oncol Biol Phys 43: pp. 763-775 CrossRef
  9. Gunderson, LL, Tepper, JE (2012) Clinical radiation cncology. Elsevier Saunders, Philadelphia
  10. Walsh, JW, Goplerud, DR (1981) Prospective comparison between clinical and CT staging in primary cervical carcinoma. Am J Roentgenol 137: pp. 997-1003 CrossRef
  11. Hricak, H, Lacoy, CG, Sandles, LG (1988) Invasive cervical carcinoma: comparison of MR imaging and surgical findings. Radiology 166: pp. 623-631 CrossRef
  12. Greco, A, Mason, P, Leung, AW (1989) Staging of carcinoma of the uterine cervix: MRI-surgical correlation. Clin Radiol 40: pp. 401-405 CrossRef
  13. Togashi, K, Nishimura, K, Sagoh, T (1989) Carcinoma of the cervix: staging with MR imaging. Radiology 171: pp. 245-251 CrossRef
  14. Koyama, T, Tamai, K, Togashi, K (2007) Staging of carcinoma of the uterine cervix and endometrium. Eur Radiol 17: pp. 2009-2019 CrossRef
  15. Flueckiger, F, Ebner, F, Poschauko, H (1992) Cervical cancer: serial MR imaging before and after primary radiation therapy鈥攁 2-year follow-up study. Radiology 184: pp. 89-93 CrossRef
  16. Hatano, K, Sekiya, Y, Araki, H (1999) Evaluation of the therapeutic effect of radiotherapy on cervical cancer using magnetic resonance imaging. Int J Radiat Oncol Biol Phys 45: pp. 639-644 CrossRef
  17. Hricak, H, Gatsonis, C, Chi, DS (2005) Role of imaging in pretreatment evaluation of early invasive cervical cancer: results of the intergroup study American College of Radiology Imaging Network 6651-Gynecologic Oncology Group 183. J Clin Oncol 23: pp. 9329-9337 CrossRef
  18. Pecorelli, S, Zigliani, L, Odicino, F (2009) Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet 105: pp. 107-108 CrossRef
  19. Patel, CN, Nazir, SA, Khan, Z (2011) 18F-FDG PET/CT of cervical carcinoma. Am J Roentgenol 196: pp. 1225-1233 CrossRef
  20. Grigsby, PW, Dehdashti, F, Siegel, BA (1999) FDG-PET evaluation of carcinoma of the cervix. Clin Positron Imaging 2: pp. 105-109 CrossRef
  21. Grigsby, PW, Siegel, BA, Dehdashti, F (2001) Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol 19: pp. 3745-3749
  22. Tran, BN, Grigsby, PW, Dehdashti, F (2003) Occult supraclavicular lymph node metastasis identified by FDG-PET in patients with carcinoma of the uterine cervix. Gynecol Oncol 90: pp. 572-576 CrossRef
  23. Hope, AJ, Saha, P, Grigsby, PW (2006) FDG-PET in carcinoma of the uterine cervix with endometrial extension. Cancer 106: pp. 196-200 CrossRef
  24. Grigsby, PW, Siegel, BA, Dehdashti, F (2004) Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol 22: pp. 2167-2171 CrossRef
  25. Schwarz, JK, Siegel, BA, Dehdashti, F (2007) Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA 298: pp. 2289-2295 CrossRef
  26. Sakurai, H, Suzuki, Y, Nonaka, T (2006) FDG-PET in the detection of recurrence of uterine cervical carcinoma following radiation therapy鈥攖umor volume and FDG uptake value. Gynecol Oncol 100: pp. 601-607 CrossRef
  27. Uzan, C, Souadka, A, Gouy, S (2011) Analysis of morbidity and clinical implications of laparoscopic para-aortic lymphadenectomy in a continuous series of 98 patients with advanced-stage cervical cancer and negative PET-CT imaging in the para-aortic area. Oncologist 16: pp. 1021-1027 CrossRef
  28. Lee, LJ, Das, IJ, Higgins, SA (2012) American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part III: low-dose-rate and pulsed-dose-rate brachytherapy. Brachytherapy 11: pp. 53-57 CrossRef
  29. Sarkaria, JN, Petereit, DG, Stitt, JA (1994) A comparison of the efficacy and complication rates of low dose-rate versus high dose-rate brachytherapy in the treatment of uterine cervical carcinoma. Int J Radiat Oncol Biol Phys 30: pp. 75-82 CrossRef
  30. Fowler, JF (1989) The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 62: pp. 679-694 CrossRef
  31. Chatani, M, Matayoshi, Y, Masaki, N (1994) A prospective randomized study concerning the point A dose in high-dose rate intracavitary therapy for carcinoma of the uterine cervix. The final results. Strahlenther Onkol 170: pp. 636-642
  32. Teshima, T, Inoue, T, Ikeda, H (1993) High-dose rate and low-dose rate intracavitary therapy for carcinoma of the uterine cervix. Final results of Osaka University Hospital. Cancer 72: pp. 2409-2414 CrossRef
  33. Hareyama, M, Sakata, K, Oouchi, A (2002) High-dose-rate versus low-dose-rate intracavitary therapy for carcinoma of the uterine cervix: a randomized trial. Cancer 94: pp. 117-124 CrossRef
  34. Lertsanguansinchai, P, Lertbutsayanukul, C, Shotelersuk, K (2004) Phase III randomized trial comparing LDR and HDR brachytherapy in treatment of cervical carcinoma. Int J Radiat Oncol Biol Phys 59: pp. 1424-1431 CrossRef
  35. Wang, X, Liu, R, Ma, B (2010) High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer. Cochrane Database Syst Rev.
  36. Potter, R, Knocke, TH, Fellner, C (2000) Definitive radiotherapy based on HDR brachytherapy with iridium 192 in uterine cervix carcinoma: report on the Vienna University Hospital findings (1993-1997) compared to the preceding period in the context of ICRU 38 recommendations. Cancer Radiother 4: pp. 159-172 CrossRef
  37. Muschitz, S, Petrow, P, Briot, E (2004) Correlation between the treated volume, the GTV and the CTV at the time of brachytherapy and the histopathologic findings in 33 patients with operable cervix carcinoma. Radiother Oncol 73: pp. 187-194 CrossRef
  38. Haie-Meder, C, Potter, R, Limbergen, E (2005) Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol 74: pp. 235-245 CrossRef
  39. Potter, R, Haie-Meder, C, Limbergen, E (2006) Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol 78: pp. 67-77 CrossRef
  40. Lang, S, Nulens, A, Briot, E (2006) Intercomparison of treatment concepts for MR image assisted brachytherapy of cervical carcinoma based on GYN GEC-ESTRO recommendations. Radiother Oncol 78: pp. 185-193 CrossRef
  41. Dimopoulos, JC, Schirl, G, Baldinger, A (2009) MRI assessment of cervical cancer for adaptive radiotherapy. Strahlenther Onkol 185: pp. 282-287 CrossRef
  42. Kirisits, C, Lang, S, Dimopoulos, J (2006) Uncertainties when using only one MRI-based treatment plan for subsequent high-dose-rate tandem and ring applications in brachytherapy of cervix cancer. Radiother Oncol 81: pp. 269-275 CrossRef
  43. Viswanathan, AN, Dimopoulos, J, Kirisits, C (2007) Computed tomography versus magnetic resonance imaging-based contouring in cervical cancer brachytherapy: results of a prospective trial and preliminary guidelines for standardized contours. Int J Radiat Oncol Biol Phys 68: pp. 491-498 CrossRef
  44. Nesvacil, N, Potter, R, Sturdza, A (2012) Adaptive image guided brachytherapy for cervical cancer: a combined MRI-/CT-planning technique with MRI only at first fraction. Radiother Oncol 107: pp. 75-81 CrossRef
  45. Katz, A, Eifel, PJ (2000) Quantification of intracavitary brachytherapy parameters and correlation with outcome in patients with carcinoma of the cervix. Int J Radiat Oncol Biol Phys 48: pp. 1417-1425 CrossRef
  46. Clark, BG, Souhami, L, Roman, TN (1997) The prediction of late rectal complications in patients treated with high dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 38: pp. 989-993 CrossRef
  47. Chen, SW, Liana, JA, Yang, SN (2000) The prediction of late rectal complications following the treatment of uterine cervical cancer by high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 47: pp. 955-961 CrossRef
  48. Chen, SW, Liang, JA, Hung, YC (2009) Geometrical sparing factors for the rectum and bladder in the prediction of grade 2 and higher complications after high-dose-rate brachytherapy for cervical cancer. Int J Radiat Oncol Biol Phys 75: pp. 1335-1343 CrossRef
  49. Nag, S, Chao, SC, Erickson, B (2002) The American Brachytherapy Society recommendations for low-dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 52: pp. 33-48 CrossRef
  50. Wachter-Gerstner, N, Wachter, S, Reinstadler, E (2003) Bladder and rectum dose defined from MRI based treatment planning for cervix cancer brachytherapy: comparison of dose-volume histograms for organ contours and organ wall, comparison with ICRU rectum and bladder reference point. Radiother Oncol 68: pp. 269-276 CrossRef
  51. Georg, P, Potter, R, Georg, D (2012) Dose effect relationship for late side effects of the rectum and urinary bladder in magnetic resonance image-guided adaptive cervix cancer brachytherapy. Int J Radiat Oncol Biol Phys 82: pp. 653-657 CrossRef
  52. Georg, P, Lang, S, Dimopoulos, JC (2011) Dose-volume histogram parameters and late side effects in magnetic resonance image-guided adaptive cervical cancer brachytherapy. Int J Radiat Oncol Biol Phys 79: pp. 356-362 CrossRef
  53. Potter, R, Dimopoulos, J, Georg, P (2007) Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer. Radiother Oncol 83: pp. 148-155 CrossRef
  54. Lindegaard, JC, Tanderup, K, Nielsen, SK (2008) MRI-guided 3D optimization significantly improves DVH parameters of pulsed-dose-rate brachytherapy in locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 71: pp. 756-764 CrossRef
  55. Narayan, K, Dyk, S, Bernshaw, D (2009) Comparative study of LDR (Manchester system) and HDR image-guided conformal brachytherapy of cervical cancer: patterns of failure, late complications, and survival. Int J Radiat Oncol Biol Phys 74: pp. 1529-1535 CrossRef
  56. Jrgenliemk-Schulz, IM, Lang, S, Tanderup, K (2010) Variation of treatment planning parameters (D90 HR-CTV, D 2cc for OAR) for cervical cancer tandem ring brachytherapy in a multicentre setting: comparison of standard planning and 3D image guided optimisation based on a joint protocol for dose-volume constraints. Radiother Oncol 94: pp. 339-345 CrossRef
  57. Nomden, C, Leeuw, AA, Limbergen, E (2012) Multicentre treatment planning study of MRI-guided brachytherapy for cervical cancer: comparison between tandem-ovoid applicator users. Radiother Oncol 107: pp. 82-87 CrossRef
  58. Charra-Brunaud, C, Harter, V, Delannes, M (2012) Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: results of the French STIC prospective study. Radiother Oncol 103: pp. 305-313 CrossRef
  59. Simpson, D, Vashar, CM, Kannan, N (2012) CT and MRI-based image guided brachytherapy for cervical cancer: a multi-institutional report. Int J Radiat Oncol Biol Phys 84: pp. S19 CrossRef
  60. Dimopoulos, JC, Potter, R, Lang, S (2009) Dose-effect relationship for local control of cervical cancer by magnetic resonance image-guided brachytherapy. Radiother Oncol 93: pp. 311-315 CrossRef
  61. Potter, R, Georg, P, Dimopoulos, JC (2011) Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. Radiother Oncol 100: pp. 116-123 CrossRef
  62. Schmid, MP, Kirisits, C, Nesvacil, N (2011) Local recurrences in cervical cancer patients in the setting of image-guided brachytherapy: a comparison of spatial dose distribution within a matched-pair analysis. Radiother Oncol 100: pp. 468-472 CrossRef
  
• 刊物主题：Oncology; Imaging / Radiology; Cancer Research; Surgical Oncology; Surgery; Radiotherapy;
• 出版者：Springer Berlin Heidelberg
• ISSN：1948-7908

文摘

Over the past century, definitive management of unresectable cervical cancer has evolved and currently employs high-dose radiation treatment with teletherapy and intracavitary brachytherapy (ICBT) components, combined with concurrent chemotherapy. Reflecting high disease prevalence among developing nations, the International Federation of Gynecology and Obstetrics (FIGO) staging of cervical cancer relies on clinical assessment, with limited radiographic studies. However, multiple clinicopathologic analyses describe suboptimal correlation between clinical examination findings and pathologic stage. Over the past two decades, systematic evaluation of volumetric and functional imaging modalities including CT, MRI, and PET-CT has refined our ability to define disease extent and provide posttreatment surveillance. Similarly, traditional ICBT techniques relied on two-dimensional (2D) data for evaluation of target dose coverage and offered limited assessment of exposure to critical structures including the bladder, rectum, and sigmoid colon. During the last several years, investigators at leading European centers have enhanced the capabilities of existing ICBT techniques through dose optimization [high-dose rate (HDR) and pulsed dose rate (PDR)] and by incorporating volumetric imaging methods. Early results are encouraging, from both toxicity and tumor control perspectives. These techniques are currently being adopted in multiple centers. Pertinent aspects are summarized in the body of this report.